non-alcoholic fatty liver disease (NAFLD)

news

DNA methylation could determine liver disease progression

21 September 2021 | By Anna Begley (Drug Target Review)

DNA methylation at specific genomic sites was found to correlate with non-fatty liver disease and could be used to diagnose severity.

news

Label-free technique used to visualise lipid content in mouse livers

21 April 2021 | By Victoria Rees (Drug Target Review)

Researchers have successfully used label-free near-infrared hyperspectral imaging for mouse livers, which could aid in the diagnosis of NAFLD.

news

New liver-on-a-chip model successfully mimics NAFLD

11 March 2021 | By Victoria Rees (Drug Target Review)

A liver-on-a-chip model has been developed to more fully represent the natural progression of NAFLD than previous models.

news

In vitro model could aid the development of fatty liver disease treatments

26 January 2021 | By Hannah Balfour (Drug Target Review)

The patient-derived model of non-alcoholic fatty liver disease (NAFLD) accurately reproduced the complex human metabolic pathways involved in the development of the disease.

article

Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates

4 June 2020 | By Aslihan Gokaltun (Harvard Medical School and Shriners Hospitals for Children), Beyza Bulutoglu (Harvard Medical School and Shriners Hospitals for Children), Camilo Rey-Bedón (Harvard Medical School and Shriners Hospitals for Children), Martin L Yarmush (Harvard Medical School and Shriners Hospitals for Children), Osman Berk Usta (Harvard Medical School and Shriners Hospitals for Children), Peony Banik (Harvard Medical School and Shriners Hospitals for Children)

The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.

news

Novel compound improves symptoms of fatty liver disease in mice

2 June 2020 | By Hannah Balfour (Drug Target Review)

The novel peripheral serotonin antagonist, based on Parkinson’s drug pimavanserin, increased glucose tolerance and lean body mass in a murine model of non-alcoholic fatty liver disease (NAFLD).

article

Screening In-Depth Focus 2020

26 May 2020 | By Drug Target Review

Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics as a map to guide drug discovery and a novel in vitro model to screen potential treatments for non-alcoholic fatty liver disease (NAFLD).

news

PPARγ identified as liver fibrosis ‘off-switch’ in mice

27 January 2020 | By Hannah Balfour (Drug Target Review)

A study identifying transcription factor differences in the hepatic stellate cells of mice with liver fibrosis named PPARγ as a potential target for the condition’s regression and scar resolution therapies.

news

New treatments for liver disease could be identified with lab-on-a-chip

30 August 2019 | By Rachael Harper (Drug Target Review)

New lab on a chip technology has been developed to evaluate the effects of different drivers of NAFLD on liver cells.